You´re viewing a limited number of results due to a fault in our system
Viewing results for Biomics LLC1‒25 of 300
Deal for health software company would be most valuable leveraged buyout in healthcare sector this year
The city’s ecosystem of universities, commerce and research is attracting investors and start-ups
UK initiative to harness big biological data sets and look deeper into how the human body works and malfunctions
Sam Altman’s OpenAI provides a test of non-profit legal structures
Private equity firms prepare to exit investments after being constrained by high interest rates
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
Research suggests the price of treating illnesses related to building of computing infrastructure in the US is on the rise
Lab assistant powered by artificial intelligence can help generate scientific hypotheses
Simon Kohl aims to capitalise on his experience with Nobel-recognised AlphaFold protein prediction system
From Professor Anton van der Merwe, Sir William Dunn School of Pathology, University of Oxford, Oxfordshire, UK
Antitrust worries prompt seller to cool on higher offer from UnitedHealth
The San Francisco-based start-up plans to get its first drug into trials this year
Putting the “loco” in relocation
From Professor Rodrigo Ledesma Amaro, Director of the Bezos Centre for Sustainable Protein, Imperial College London, London SW7, UK
From Dr David Ross, Consultant Physician, Stornoway, Outer Hebrides, UK
JPMorgan event follows the murder of an industry leader and the nomination of a vaccine sceptic as top official
Founder of Isomorphic Labs aims to develop a drug in oncology, cardiovascular or neurodegeneration areas
Verdiva Bio wants to use potential drugs acquired in China to compete in growing obesity market
From Neil Ward, Vice-President and General Manager Emea, PacBio, London N7, UK
From Sandra P Smieszek, PhD Geneticist, Washington, DC, US
‘MiniLife’ research extends growing field of synthetic biology into new territory
Medical tech is increasingly mainstream but needs path to profitability
The multibillion-dollar longevity industry, a coven of snake oil merchants, biohackers and geniuses, is tricky to quantify
The progress of new discoveries must be celebrated
Deal with BC Partners aims to capitalise on rising demand for off-patent versions of complex drugs